News from vanda pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 10, 2015, 07:00 ET

Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Aug 05, 2015, 07:00 ET

HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced publication of pivotal trial results related to patient entrainment in the...

Aug 03, 2015, 07:00 ET

Vanda Announces Listing of Four New Fanapt® Patents in the FDA Orange Book

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that four new Fanapt® patents are now listed in the U.S. Food and Drug...

Jul 29, 2015, 16:01 ET

Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30,...

Jul 09, 2015, 09:00 ET

Vanda Pharmaceuticals to Announce Second Quarter 2015 Financial Results on July 29, 2015

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2015 on Wednesday, July...

Jul 07, 2015, 16:30 ET

HETLIOZ® Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the European Commission (EC) approved HETLIOZ® (tasimelteon) for...

Jul 02, 2015, 09:00 ET

Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a HETLIOZ® patent, number 9,060,995 ('995 patent), is now...

Jun 23, 2015, 16:30 ET

Vanda Announces Positive Results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) Demonstrating the Long-Term Maintenance Effects of Fanapt® (iloperidone)

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today presented positive results from the long-term maintenance REPRIEVE (Relapse...

Jun 19, 2015, 09:32 ET

Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Jun 02, 2015, 17:00 ET

Vanda Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products...

May 26, 2015, 17:00 ET

Vanda Receives Innovation Award from the National Organization for Rare Disorders for Development of HETLIOZ®

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has received the 2015 Industry Innovation Award from the National...

May 11, 2015, 16:30 ET

Vanda Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

May 06, 2015, 16:01 ET

Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31,...

Apr 27, 2015, 08:14 ET

Vanda recibe opinión para HETLIOZ® (tasimelteon) para tratar la enfermedad del sueño retrasado non-24-horas

- Vanda recibe la opinión positiva del CHMP para HETLIOZ® (tasimelteon) para el tratamiento de la enfermedad del sueño retrasado...

Apr 25, 2015, 06:44 ET

Vanda obtient un avis favorable du CHMP pour HETLIOZ® (tasimelteon) en vue du traitement du syndrome hyper-nycthéméral au sein de l'Union européenne

- HETLIOZ®, un régulateur circadien, est le premier et le seul produit à recevoir une recommandation d'approbation pour le...

Apr 24, 2015, 14:22 ET

Vanda erhält positive Stellungnahme des CHMP für HETLIOZ® (Tasimelteon) zur Behandlung der Schlaf-Wach-Störung bei Abweichung vom 24-Stunden-Rhythmus in der Europäischen Union

- HETLIOZ®, ein Arzneimittel zur Synchronisation des 24-Stunden-Rhythmus, ist das erste und einzige Produkt, das in der Europäischen...

Apr 24, 2015, 07:44 ET

Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products...

Apr 20, 2015, 08:00 ET

Vanda Pharmaceuticals Announces the Appointment of Chief Commercial Officer

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Tom Gibbs as Senior Vice President, Chief Commercial Officer of...

Apr 16, 2015, 17:30 ET

Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the...

Apr 13, 2015, 17:45 ET

Vanda Announces Trial Date for Fanapt® Patent Cases

 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced a February 29, 2016 trial date for two pending cases against Roxane...